Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists-Reference-Cited by-同舟云学术

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists

Published:2016-11-30 Issue: Volume:12 Page:5-12
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia-Pac J Clin Oncol

Author:

Atkinson Victoria¹,Long Georgina V.²,Menzies Alexander M.²,McArthur Grant³,Carlino Matteo S.⁴,Millward Michael⁵,Roberts-Thomson Rachel⁶,Brady Benjamin³,Kefford Richard⁷,Haydon Andrew⁸,Cebon Jonathan⁹

Affiliation:

1. Princess Alexandra Hospital; Greenslopes Private Hospital and University of Queensland; Brisbane Queensland Australia

2. Melanoma Institute Australia; Royal North Shore and Mater Hospitals; The University of Sydney; Sydney New South Wales Australia

3. Peter MacCallum Cancer Centre and Cabrini Health; Melbourne Victoria Australia

4. Westmead Hospital; Sydney New South Wales Australia

5. School of Medicine and Pharmacology; University of Western Australia and Sir Charles Gairdner Hospital; Perth Western Australia Australia

6. Queen Elizabeth Hospital; Adelaide South Australia Australia

7. Westmead Hospital and Macquarie University; Sydney New South Wales Australia

8. The Alfred Hospital; Melbourne Victoria Australia

9. Olivia Newton John Cancer Wellness & Research Centre; Austin Health Melbourne; Victoria Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ajco.12656/fullpdf

Reference32 articles.

1. The molecular profile of metastatic melanoma in Australia;Lyle;Pathology,2016

2. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists;Kakavand;Pathology,2016

3. Inhibition of mutated, activated BRAF in metastatic melanoma;Flaherty;N Engl J Med,2010

4. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma;Ascierto;J Clin Oncol,2013

5. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial;Falchook;Lancet Oncol,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Toxicities from BRAF and MEK Inhibitors: Strategies to Maximize Therapeutic Success;Current Oncology Reports;2024-06-08

2. Systemic Treatment of Melanoma;Rook's Textbook of Dermatology;2024-03-19

3. Case 2-2024: A 57-Year-Old Woman with Melanoma and Fever;New England Journal of Medicine;2024-01-18

4. BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes;European Journal of Cancer;2023-01

5. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib forBRAFV600–Mutant Unresectable or Metastatic Melanoma;Journal of Clinical Oncology;2022-05-01